Literature DB >> 22249957

Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009.

Takashi Yoshio1, Toshiya Inada, Junji Uno, Takaichi Miwa, Kohei Kitagawa, Yoshiki Miyahara, Kenta Umeda, Tsuyoshi Kato, Ataru Inagaki, Toshitaka Nabeshima.   

Abstract

BACKGROUND AND
OBJECTIVE: Pharmacological treatment of schizophrenic patients in Japan is characterized by polypharmacy with high doses of antipsychotics. In this study, we examined the profiles of antipsychotic drug therapy in 2007 and 2009 to determine if there have been any recent shifts in treatment strategy.
METHOD: The subjects were schizophrenic inpatients (ICD-10-F20) admitted to 100 hospitals in 2007 and 152 hospitals in 2009. Information on the psychotropic agents prescribed on specified days in November 2007 and 2009 was acquired for each patient.
RESULTS: Although no changes were observed in the rate of antipsychotic medications being prescribed, the rate of antipsychotic monotherapy in 2009 increased significantly. In 2007, among 15,761 patients, 4977 (31.6%) received antipsychotic monotherapy (i.e., administration of a single antipsychotic medication). In 2009, among 22,911 patients, 7741 (33.8%) received antipsychotic monotherapy.
CONCLUSION: The rate of use of antipsychotic monotherapy has gradually increased, although the total dose has not changed significantly. The increase in the concomitant use of two or more second-generation antipsychotics is a recent trend in Japan, despite the lack of information on the efficacy and safety of this treatment strategy.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249957     DOI: 10.1002/hup.1272

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  12 in total

1.  Effect of COMT Val108/158Met genotype on risk for polydipsia in chronic patients with schizophrenia.

Authors:  Kenji Yamada; Takahiro Shinkai; Hsin-I Chen; Kensuke Utsunomiya; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2014-01-18       Impact factor: 3.843

2.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

3.  Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.

Authors:  Hikaru Hori; Norio Yasui-Furukori; Naomi Hasegawa; Jun-Ichi Iga; Shinichiro Ochi; Kayo Ichihashi; Ryuji Furihata; Yoshitaka Kyo; Yoshikazu Takaesu; Takashi Tsuboi; Fumitoshi Kodaka; Toshiaki Onitsuka; Tsuyoshi Okada; Atsunobu Murata; Hiroko Kashiwagi; Hitoshi Iida; Naoki Hashimoto; Kazutaka Ohi; Hisashi Yamada; Kazuyoshi Ogasawara; Yuka Yasuda; Hiroyuki Muraoka; Masahide Usami; Shusuke Numata; Masahiro Takeshima; Hirotaka Yamagata; Tatsuya Nagasawa; Hiromi Tagata; Manabu Makinodan; Mikio Kido; Eiichi Katsumoto; Hiroshi Komatsu; Junya Matsumoto; Chika Kubota; Kenichiro Miura; Akitoyo Hishimoto; Koichiro Watanabe; Ken Inada; Hiroaki Kawasaki; Ryota Hashimoto
Journal:  Front Psychiatry       Date:  2022-05-17       Impact factor: 5.435

4.  Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Hiroyuki Uchida; Masaru Mimura; John M Kane; Christoph U Correll
Journal:  Psychiatry Res       Date:  2013-04-18       Impact factor: 3.222

5.  Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.

Authors:  Yoshio Yamanouchi; Tsuruhei Sukegawa; Ataru Inagaki; Toshiya Inada; Takashi Yoshio; Reiji Yoshimura; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-11       Impact factor: 5.176

6.  Association between the blood concentrations of ammonia and carnitine/amino acid of schizophrenic patients treated with valproic acid.

Authors:  Masazumi Ando; Hideaki Amayasu; Takahiro Itai; Hisahiro Yoshida
Journal:  Biopsychosoc Med       Date:  2017-07-05

7.  The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia.

Authors:  Ryoko Nakagawa; Takashi Ohnishi; Hisanori Kobayashi; Akihide Wakamatsu; Ai Tanimura; Kazuo Morita; Toshio Yamaoka; Hideo Usui; Yoshimasa Ogawa; Akiko Fujino; Kazutake Yoshizawa
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-22       Impact factor: 2.570

8.  Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.

Authors:  Tsuruhei Sukegawa; Ataru Inagaki; Yoshio Yamanouchi; Toshiya Inada; Takashi Yoshio; Reiji Yoshimura; Nakao Iwata
Journal:  BMC Psychiatry       Date:  2014-04-07       Impact factor: 3.630

Review 9.  Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?

Authors:  Shih-Ku Lin
Journal:  Int J Neuropsychopharmacol       Date:  2020-02-01       Impact factor: 5.176

10.  Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study.

Authors:  Nobutaka Ayani; Takeshi Morimoto; Mio Sakuma; Toshiaki Kikuchi; Koichiro Watanabe; Jin Narumoto
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.